FrancophonIA/ELRC3.0 huggingface dataset:
English: Children (non approved use) and patients with underlying neuromuscular disorders including swallowing disorders are at increased risk of these adverse reactions.
Croatian: Rizik od tih nuspojava povećan je u djece (neodobrena primjena) i bolesnika s već postojećim neuromuskularnim poremećajima uključujući poremećaje gutanja.
English: In the first study, type A resistant patients (A-non responders) were randomised to receive placebo or 10,000 U of NeuroBloc and in the second, type A toxin responsive patients (A-responders) were randomised to receive placebo, 5000 U or 10,000 U of toxin.
Croatian: U prvom ispitivanju bolesnici rezistentni na tip A (bez odgovora na A) bili su randomizirani u skupinu koja je primala placebo ili u skupinu koja je primala 10 000 U NeuroBloca, a u drugom ispitivanju, bolesnici s odgovorom na toksin tipa
English: Lack of interchangeability between botulinum toxin products The initial starting dose of 10,000 U (or 5000 U) is relevant only to NeuroBloc (Botulinum Toxin Type B).
Croatian: Početna doza od 10 000 U (ili 5000 U) odnosi se samo na NeuroBloc (botulinski toksin tipa B).
English: This may occur when higher doses of up to 15,000 units are given if you have difficulty breathing or you are worried by any symptoms you develop away from the place of the injection, talk to your doctor immediately.
Croatian: Ako imate poteškoća s disanjem ili ste zabrinuti zbog nekog simptoma koji se razvio daleko od mjesta injekcije, odmah se obratite liječniku.
English: EXP After dilution, use immediately
Croatian: Upotrijebiti odmah nakon razrjeđivanja.
English: The second study enrolled patients who continued to respond to type A toxin (A-responders).
Croatian: Drugo ispitivanje uključilo je bolesnike u kojih se i dalje postizao odgovor na toksin tipa
English: Any unused solution, all vials of expired NeuroBloc and equipment used in the administration of the medicinal product should be carefully discarded as Medical Biohazardous Waste in accordance with local requirements.
Croatian: Svu neupotrijebljenu otopinu, sve bočice lijeka NeuroBloc kojima je istekao rok valjanosti i pribor upotrijebljen za primjenu lijeka treba pažljivo zbrinuti kao opasan medicinski otpad u skladu s lokalnim propisima.
English: However, the clinical relevance of the presence of antibodies as determined by the mouse neutralisation / mouse protection assay is uncertain.
Croatian: Međutim, kliničko značenje prisutnosti protutijela, kako je određeno testom neutralizacije u miševa/zaštite miševa, nije pouzdano ustanovljeno.
English: To allow division of the total dose between several injections, NeuroBloc may be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection and the solution used immediately.
Croatian: Da bi bilo moguće raspodijeliti ukupnu dozu na nekoliko injekcija, NeuroBloc se može razrijediti 0,9%-tnom otopinom natrijevog klorida za injekcije (9 mg/ml), a otopinu je potrebno upotrijebiti odmah.
English: NeuroBloc 5000 U/ml Solution for Injection Botulinum Toxin Type B
Croatian: NeuroBloc 5000 U/ml otopina za injekciju botulinski toksin tipa B
English: NeuroBloc should only be administered by a physician who is familiar with and experience in the treatment of cervical dystonia and in the use of botulinum toxins.
Croatian: NeuroBloc smiju primjenjivati samo liječnici sa znanjem i iskustvom u liječenju cervikalne distonije te primjeni botulinskih toksina.
English: Gastrointestinal disorders dysphagia dyspepsia
Croatian: Poremećaji probavnog sustava disfagija dispepsija
English: How to use NeuroBloc
Croatian: Kako primjenjivati NeuroBloc
English: However, the clinical relevance of the presence of antibodies as determined by the mouse neutralisation/ mouse protection assay is uncertain.
Croatian: Međutim, kliničko značenje prisutnosti protutijela ustanovljeno testom neutralizacije u miševa/zaštita miševa ostaje nedovoljno razjašnjeno.
English: To allow division of the total dose between several injections, NeuroBloc may be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection (see section 4.2).
Croatian: Da bi se omogućila raspodjela ukupne doze na nekoliko injekcija, NeuroBloc se može razrijediti 0,9%-tnom otopinom natrijevog klorida za injekcije (9 mg/ml) (vidjeti dio 4.2).
English: Analysis of the TWSTRS sub scales revealed significant effects on the severity of cervical dystonia and its associated pain and disability.
Croatian: Rezultati usporedbi primarnih i sekundarnih varijabli djelotvornosti sažeto su prikazani u tablici 1. Analiza podljestvica TWSTRS pokazala je značajne učinke na težinu cervikalne distonije i pridruženu bol i invalidnost.
English: How to store NeuroBloc
Croatian: Kako čuvati NeuroBloc
English: To allow division of the total dose between several injections, NeuroBloc may be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection (see section 4.2 of Summary of Product Characteristics).
Croatian: Kako bi se ukupna doza mogla razdijeliti na nekoliko injekcija, NeuroBloc se može razrijediti 0,9%-tnom otopinom natrijevog klorida za injekcije (9 mg/ml) (vidjeti dio 4.2 Sažetka opisa svojstava lijeka).
English: Respiratory thoracic and mediastinal disorders dysphonia
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja disfonija
English: How NeuroBloc is given
Croatian: Kako se daje NeuroBloc
English: System Organ Class
Croatian: Klasifikacija organskih sustava Vrlo često
English: Following local intramuscular injection of NeuroBloc serious adverse events that may have been due to systemic effects of Botulinum Toxin Type B, were observed in 12% of adverse reaction cases reported during the post-marketing experience (including the following adverse reactions: dry mouth, dysphagia and blurred vision).
Croatian: B opaženi su u 12% slučajeva nuspojava prijavljenih tijekom iskustva nakon stavljanja lijeka u promet (uključujući sljedeće nuspojave: suha usta, disfagija i zamagljen vid).
English: Do not freeze keep the vial in the outer carton in order to protect from light within its shelf-life, NeuroBloc may be removed from the refrigerator for a single period of up to 3 months at a temperature not above 25oC.
Croatian: Unutar roka valjanosti, NeuroBloc može biti izvan hladnjaka tijekom jednokratnog razdoblja do 3 mjeseca na temperaturi koja ne prelazi 25°C.
English: This means it is essentially “sodium free”.
Croatian: To znači da zapravo ne sadrži natrij.
English: Standard tests to investigate the mutagenicity of NeuroBloc have not been performed.
Croatian: Standardni testovi za istraživanje mutagenosti
English: PHARMACEUTICAL FORM
Croatian: NAČIN PRIMJENE LIJEKA
English: The extent and time course of seroconversion were similar in patients with prior toxin A exposure and those who were toxin A naïve, and between toxin A resistant and toxin A responsive patients.
Croatian: Opseg i tijek serokonverzije bili su slični u bolesnika s prethodnim izlaganjem toksinu
English: Human serum albumin Hydrochloric acid (for pH adjustment) Water for injections
Croatian: FARMACEUTSKI PODACI 6.1 Popis pomoćnih tvari dinatrijev sukcinat natrijev klorid humani serumski albumin kloridna kiselina (za podešavanje pH) voda za injekcije
English: NeuroBloc 5000 U/ml solution for injection IM
Croatian: NeuroBloc 5000 U/ml otopina za injekciju i.m.
English: This is because it is not known how NeuroBloc affects patients who are pregnant and it is not known if NeuroBloc passes into a nursing mother's breast milk if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine
Croatian: Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku ili ljekarniku za savjet prije nego što primite ovaj lijek.
English: Both studies enrolled adult patients (³ 18 years) who had a history of receiving Botulinum Toxin Type A. The first study enrolled patients who were clinically resistant to type A toxin (A-non responders), confirmed by a Frontalis Type A test.
Croatian: Prvo ispitivanje uključilo je bolesnike klinički rezistentne na toksin tipa A (bez odgovora na A), potvrđeno testom Frontalis tip A.
English: If there are any visible signs of deterioration, the medicine should not be used, but discarded any unused solution should be discarded due to the special nature of NeuroBloc, the doctor will ensure that all used vials, needles and syringes must be processed as Medical Biohazardous Waste in accordance with local requirements
Croatian: Zbog posebne naravi lijeka NeuroBloc, liječnik će paziti da se sa svim upotrijebljenim bočicama, iglama i štrcaljkama postupa kao s opasnim medicinskim otpadom u skladu s lokalnim propisima.
English: Each ml contains 5000 U Botulinum Toxin Type B.
Croatian: Jedan ml sadrži 5000 U botulinskog toksina tipa B.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 0.5 ml vial
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA, bočica od 0,5 ml
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 1.0 ml vial
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA, bočica od 1,0 ml
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL 0.5 ml vial
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA BOČICE OD 0,5 ml
English: There have been spontaneous reports of dysphagia, aspiration pneumonia and/or potentially fatal respiratory disease, after treatment with Botulinum Toxin Type A/B.
Croatian: Nakon liječenja botulinskim toksinom tipa A/B bilo je spontanih izvještaja o disfagiji, aspiracijskoj pneumoniji i/ili potencijalno smrtonosnoj respiratornoj bolesti.
English: MARKETING AUTHORISATION HOLDER
Croatian: Nositelj odobrenja za stavljanje lijeka u promet
English: Marketing Authorisation holder
Croatian: NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL 1.0 ml vial
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNICA BOČICE OD 1,0 ml
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON 2.0 ml vial
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA, bočica od 2,0 ml
English: Each 0.5 ml vial contains 2500 U Botulinum Toxin Type B.
Croatian: Jedna bočica od 0,5 ml sadrži 2500 U botulinskog toksina tipa B.
English: Physician Global
Croatian: Liječnička opća procjena
English: At the end of this period, the product should not be put back in the refrigerator and should be disposed of the date at which the medicine was taken out from the refrigerator will be put on the outer carton if the medicine is diluted, the doctor will use it immediately before using the medicine the doctor will check that the solution is clear and colourless/light yellow.
Croatian: Prije primjene lijeka liječnik će provjeriti je li otopina bistra i bezbojna/svijetložuta.
English: Each 2.0 ml vial contains 10,000 U Botulinum Toxin Type B.
Croatian: Jedna bočica od 2,0 ml sadrži 10 000 U botulinskog toksina tipa B.
English: Each 1.0 ml vial contains 5000 U Botulinum Toxin Type B.
Croatian: Jedna bočica od 1,0 ml sadrži 5000 U botulinskog toksina tipa B.
English: In particular, tell your doctor or pharmacist if you are taking any of the following medicines: aminoglycoside antibiotics for an infection medicines to stop blood clotting, such as warfarin
Croatian: aminoglikozidni antibiotici za liječenje infekcije lijekovi za sprječavanje razvoja krvnih ugrušaka poput varfarina.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL LABEL 2.0 ml vial
Croatian: PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE NALJEPNIICA BOČICE OD 2,0 ml
English: How to store NeuroBloc keep this medicine out of the sight and reach of children do not use this medicine after the expiry date which is stated on the carton and on the vial after EXP store in a refrigerator (2°C-8°C).
Croatian: Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i bočici iza Rok valjanosti/EXP.
English: Having more injections of NeuroBloc the effects of NeuroBloc will usually last about 12 to 16 weeks your doctor will decide if you need another injection and how much to give you
Croatian: Učinci lijeka NeuroBloc obično traju oko 12 do 16 tjedana.
English: These dose units are specific to NeuroBloc only and are not relevant to preparations of Botulinum Toxin Type A. The unit dose recommendations for Botulinum Toxin Type A are significantly lower than those for NeuroBloc and administration of Botulinum Toxin Type A at the unit dose recommended for NeuroBloc may result in systemic toxicity and life-threatening clinical sequelae.
Croatian: Te jedinične doze vrijede isključivo za NeuroBloc i ne odnose se na pripravke botulinskog toksina tipa A.
English: Musculoskeletal connective tissue and bone disorders myasthenia
Croatian: Poremećaji mišićno-koštanog sustava vezivnog tkiva miastenija
English: Renal and hepatic impairment
Croatian: Oštećenje funkcije jetre i bubrega
English: Further information on Pazenir can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/pazenir.
Croatian: Više informacija o lijeku Pazenir nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/pazenir.
English: The medicine is given once a day on days 1, 8 and 15 of each cycle.
Croatian: Lijek se daje jednom dnevno 1., 8. i 15. dana svakog ciklusa.
English: Information on the reference medicine can also be found on the Agency's website.
Croatian: Informacije o referentnom lijeku također se nalaze na internetskim stranicama Agencije.
English: What is Pazenir and what is it used for?
Croatian: Što je Pazenir i za što se koristi?
English: The recommended dose depends on the patient's height and weight.
Croatian: Preporučena doza ovisi o tjelesnoj težini i visini bolesnika.
English: What measures are being taken to ensure the safe and effective use of Pazenir?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pazenir?
English: Paclitaxel has been available as a cancer medicine since 1993.
Croatian: Paklitaksel je dostupan kao lijek protiv raka od 1993.
English: Pazenir is used to treat the following cancers in adults:
Croatian: Pazenir se koristi za liječenje sljedećih vrsta raka u odraslih osoba:
English: Pazenir received a marketing authorisation valid throughout the EU on 6 May 2019.
Croatian: Lijek Pazenir dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 6. svibnja 2019.
English: It should not be interchanged with other medicines containing paclitaxel.
Croatian: Lijek se ne smije zamijeniti drugim lijekovima koji sadrže paklitaksel.
English: This makes it easy to prepare a suspension of paclitaxel, which can be infused into a vein.
Croatian: Time se olakšava priprema suspenzije paklitaksela koji se može ubrizgavati u venu.
English: Pazenir (paclitaxel)
Croatian: Pazenir (paklitaksel)
English: Immediately after giving Pazenir, gemcitabine should be given.
Croatian: Odmah nakon davanja lijeka Pazenir potrebno je dati i gemcitabin.
English: Pazenir also affects non-cancer cells such as blood and nerve cells, which can cause side effects.
Croatian: Pazenir također djeluje na ostale stanice koje nisu stanice raka, kao što su krvne i živčane stanice, što može prouzročiti nuspojave.
English: Pazenir is given as an infusion into a vein over a period of 30 minutes.
Croatian: Pazenir se daje kao intravenska infuzija tijekom 30 minuta.
English: Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Abraxane, and do not need to be repeated for Pazenir.
Croatian: Ispitivanja koristi i rizika od djelatne tvari u odobrenim primjenama već su provedena s referentnim lijekom Abraxane i stoga ih nije potrebno ponavljati za Pazenir.
English: What are the benefits and risks of Pazenir?
Croatian: Koje su koristi i rizici od lijeka Pazenir?
English: Why is Pazenir authorised in the EU?
Croatian: Zašto je lijek Pazenir odobren u EU-u?
English: For more information on generic medicines, see the question-and-answer document here.
Croatian: Više informacija o generičkim lijekovima potražite u dokumentu s pitanjima i odgovorima ovdje.
English: Side effects reported with Pazenir are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Pazenir pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: By keeping this structure intact, the cells cannot divide and they eventually die.
Croatian: Budući da ta struktura ostaje cjelovita, stanice se ne mogu dijeliti te naposljetku odumiru.
English: Paclitaxel blocks a stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide.
Croatian: Paklitaksel blokira fazu diobe stanica tijekom koje se unutarnji „kostur” stanice raspada kako bi se stanica mogla razdijeliti.
English: There was no need for ‘bioequivalence' studies to investigate whether Pazenir is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Croatian: Nisu bila potrebna ispitivanja „bioekvivalencije” kako bi se istražilo apsorbira li se lijek Pazenir slično referentnom lijeku da bi proizveo istu razinu djelatne tvari u krvi.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Pazenir has been shown to be comparable to Abraxane.
Croatian: Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da je lijek Pazenir usporediv s lijekom Abraxane.
English: An overview of Pazenir and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Pazenir i zašto je odobren u EU-u
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pazenir have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Pazenir nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: This means that Pazenir contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Abraxane.
Croatian: To znači da Pazenir sadrži istu djelatnu tvar i djeluje na jednak način kao i „referentni lijek” koji je već odobren u EU-u pod nazivom Abraxane.
English: In non-small cell lung cancer, treatment is carried out in 3-week cycles with Pazenir given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Pazenir.
Croatian: Kod raka pluća nemalih stanica liječenje se provodi u trotjednim ciklusima, pri čemu se Pazenir primjenjuje 1., 8. i 15. dana svakog ciklusa, a karboplatin se daje odmah nakon lijeka Pazenir 1. dana ciklusa.
English: • metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine;
Croatian: • metastatskog adenokarcinoma gušterače, kao prva terapija u kombinaciji s drugim lijekom protiv raka gemcitabinom;
English: Because Pazenir is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Pazenir generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: Pazenir should only be given under the supervision of a cancer doctor in clinics that are specialised in giving ‘cytotoxic' (cell-killing) medicines.
Croatian: Pazenir se smije primjenjivati samo pod nadzorom liječnika specijalista za rak u klinikama specijaliziranima za primjenu citotoksičnih lijekova (koji ubijaju stanice).
English: • non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin when the patient cannot have surgery or radiotherapy.
Croatian: • raka pluća nemalih stanica, kao prva terapija u kombinaciji s lijekom za liječenje raka karboplatinom kada bolesnik ne može biti operiran ili podvrgnut radioterapiji.
English: This is because Pazenir is given by infusion into a vein and the nanoparticles it contains rapidly separate into its constituent parts in the same way as Abraxane's.
Croatian: To je zbog toga što se Pazenir daje infuzijom u venu, pa se nanočestice koje sadrži brzo razdvajaju na svoje sastavne dijelove na isti način kao nanočestice lijeka Abraxane.
English: Other information about Pazenir
Croatian: Ostale informacije o lijeku Pazenir
English: As for every medicine, the company provided studies on the quality of Pazenir.
Croatian: Kao i za svaki lijek, tvrtka je dostavila podatke o ispitivanjima kakvoće lijeka Pazenir.
English: For more information about using Pazenir, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Pazenir pročitajte u uputi o lijeku odnosno obratite se liječniku ili ljekarniku.
English: In Pazenir, as in its reference medicine Abraxane, paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'.
Croatian: Kod lijeka Pazenir, kao i kod referentnog lijeka Abraxane, paklitaksel je pričvršćen na ljudski protein naziva albumin u obliku sitnih čestica poznatih kao „nanočestice”.
English: As for all medicines, data on the use of Pazenir are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Pazenir kontinuirano se prate.
English: Therefore, the Agency's view was that, as for Abraxane, the benefits of Pazenir outweigh the identified risks and it can be authorised for use in the EU.
Croatian: Stoga je stav Agencije da koristi od lijeka Pazenir, kao i od lijeka Abraxane, nadmašuje identificirane rizike te da lijek može biti odobren za primjenu u EU-u.
English: Pazenir contains the active substance paclitaxel attached to a human protein called albumin and is a ‘generic medicine'.
Croatian: Pazenir sadrži djelatnu tvar paklitaksel, pričvršćenu na ljudski protein naziva albumin, te je generički lijek.
English: • metastatic breast cancer, when the first treatment has stopped working and standard treatment including an anthracycline (another type of cancer medicine) is not suitable.
Croatian: • metastatskog raka dojke kada je prva terapija prestala djelovati, a standardna terapija koja uključuje antraciklin (drugi lijek protiv raka) nije prikladna. „Metastatski” znači da se rak proširio na druge dijelove tijela;
English: The active substance in Pazenir, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'.
Croatian: Djelatna tvar u lijeku Pazenir, paklitaksel, pripada taksanima, skupini lijekova protiv raka.
English: In metastatic breast cancer, Pazenir is given on its own every three weeks.
Croatian: Pazenir se daje kao monoterapija svaka tri tjedna.
English: How does Pazenir work?
Croatian: Kako djeluje Pazenir?
English: How has Pazenir been studied?
Croatian: Kako je Pazenir ispitivan?
English: How is Pazenir used?
Croatian: Kako se Pazenir primjenjuje?
English: In metastatic adenocarcinoma of the pancreas, Pazenir is given in 4-week treatment cycles.
Croatian: Pazenir se daje u ciklusima liječenja u trajanju od četiri tjedna.
English: 250 µg Solution for injection
Croatian: 250 µg Otopina za injekciju
English: Intravenous use vial (glass) 5 ml
Croatian: U venu bočica (staklo) 5 ml
English: Invented name
Croatian: (Zaštićeno) ime
English: Strength Pharmaceutical Form
Croatian: Doza Farmaceutski oblik Put primjene
English: Packaging Content (concentration) Package size
Croatian: Sastav (koncentracija)
English: It was to be available as granules.
Croatian: Trebao je biti dostupan u granulama.
English: The conditions are caused by a lack of enzymes needed to remove them.
Croatian: Ta su stanja uzrokovana manjkom enzima potrebnih za njihovo uklanjanje.
English: Prohippur was expected to be used to treat the following inherited disorders:
Croatian: Očekivalo se da će se lijek Prohippur primjenjivati za liječenje sljedećih nasljednih poremećaja: